SCHEMBL13879895

SCHEMBL13879895

CCOC(=O)c1nc(NC(=O)c2nc(N(N)Cl)cn2C)cn1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RPS6KA3 P51812 1/20 0.46
SMN1; SMN2 Q16637 4/20 0.34
HPGD P15428 3/20 0.34
NPSR1 Q6W5P4 1/20 0.34
KDM4E B2RXH2 4/20 0.34
NPC1 O15118 4/20 0.34
RAB9A P51151 4/20 0.34
HSD17B10 Q99714 2/20 0.34
TP53 P04637 1/20 0.34
WDR5 P61964 1/20 0.34
MAPT P10636 3/20 0.33
BAZ2B Q9UIF8 1/20 0.33
BAZ2A Q9UIF9 1/20 0.33
ADORA2A P29274 3/20 0.32
ADORA3 P0DMS8 2/20 0.32
ADORA1 P30542 2/20 0.32
HTT P42858 3/20 0.32
MEN1 O00255 2/20 0.32
ALDH1A1 P00352 2/20 0.32
KMT2A Q03164 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14084779 0.83 RPS6KA3 (0.47) RPS6KA3SMN1; SMN2HPGDNPSR1KDM4E
SCHEMBL14072191 0.82 RPS6KA3 (0.47) RPS6KA3SMN1; SMN2NPSR1KDM4ENPC1
SCHEMBL2390274 0.77 RPS6KA3 (0.45) RPS6KA3NPSR1KDM4ENPC1RAB9A
SCHEMBL2389890 0.77 RPS6KA3 (0.45) RPS6KA3NPSR1KDM4ENPC1RAB9A
SCHEMBL14072168 0.77 RPS6KA3 (0.48) RPS6KA3HPGDKDM4ENPC1RAB9A
SCHEMBL14072221 0.76 RPS6KA3 (0.43) RPS6KA3SMN1; SMN2HPGDNPSR1KDM4E
SCHEMBL14543376 0.76 RPS6KA3 (0.44) RPS6KA3SMN1; SMN2HPGDKDM4ENPC1
SCHEMBL10143997 0.75 SMN1; SMN2 (0.53) RPS6KA3SMN1; SMN2HPGDKDM4ENPC1
SCHEMBL13879891 0.75 RPS6KA3 (0.45) RPS6KA3HPGDKDM4EWDR5BAZ2B
SCHEMBL14072200 0.75 RPS6KA3 (0.47) RPS6KA3SMN1; SMN2HPGDKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1931671-B1 ALKYL 4- [4- (5-OXO-2, 3, 5, 11A-TETRAHYD0-5H-PYRR0L0 [2, 1-C][1, 4]BENZODIAZEPINE-8-YLOXY) -BUTYRYLAMINO]-1H-PYRROLE-2-CARBOXYLATE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF A PROLIFERATIVE DISEASE SPIROGEN LTD (GB) 2009-04-08 EP disclosed
US-20080214525-A1 Alkyl 4- [4- (5-Oxo-2,3,5, 11A-Tetrahydo-5H-Pyrrolo [2, 1-C] [1,4] Benzodiazepine-8-Yloxy) -Butyrylamino]-1H-Pyrrole-2-Carboxylate Derivatives and Related Compounds For the Treatment of a Proliferative Disease SPIROGEN LIMITED (GB) 2008-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214525-A1 Alkyl 4- [4- (5-Oxo-2,3,5, 11A-Tetrahydo-5H-Pyrrolo [2, 1-C] [1,4] Benzodiazepine-8-Yloxy) -Butyrylamino]-1H-Pyrrole-2-Carboxylate Derivatives and Related Compounds For the Treatment of a Proliferative Disease CCNY, NR0B1, CNR1 RPS6KA3 1609/4885SMN1; SMN2 1132/4885HPGD 2315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.